LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 24, 2026, 10:00 AM UTC

ATYR - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

ATYR

Related stories

BRIEF — U.S. Food And Drug Administration (FDA) Approves Lilly's Onswik, A Once — Weekly Basal Insulin Injection Treatment For Adults Living With Type 2 Diabetes Sept 24 (Reuters) — Eli Lilly and Company: U.s. Food And Drug Administration (Fda) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-gobe), A Once-weekly Basal Insulin Injection Trea L impact | REGULATION | Sep 24, 2026, 10:50 AM UTC U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin1,2With Onswik, Lilly's type 2 diabetes portfolio expands to include a once-weekly basal L impact | REGULATION | Sep 24, 2026, 10:47 AM UTC FDA Approves Eli Lilly's Onswik For Type 2 Diabetes L impact | REGULATION | Sep 24, 2026, 10:47 AM UTC LLY US FDA OKS LILLY'S ONSWIK L impact | REGULATION | Sep 24, 2026, 10:46 AM UTC UPDATE 1 — Munich Re MGA says AmTrust actions exposed it to regulatory risk in London lawsuit (Updated para 7 with decline to comment from MD/HSB) By Annabel Tinson Sept 23 (The Insurer) — MD Insurance Services has filed a claim in London's Commercial Court against AmTrust L impact | REGULATION | Sep 24, 2026, 10:46 AM UTC Eli Lilly and Company (LLY) Wins FDA Nod For Once-Weekly Basal Insulin Onswik Eli Lilly and Company received FDA approval for Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. The pen will be available in the U L impact | REGULATION | Sep 24, 2026, 10:46 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.